AHL/AO/2026/1321 **Date: 27 July 2026**

To
The Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Subject: Outcome of Analyst / Investor Webinar held on 24 July 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref.: *Scrip Code: 543943*

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the management of **Asarfi Hospital Limited** participated in an Analyst / Investor Webinar held on **24 July 2026** from **4:30 PM to 5:30 PM (IST)**.

During the webinar, the management provided an overview of the Company's business operations, financial performance, strategic initiatives and future growth prospects. The key highlights discussed during the interaction are as follows:

1. The Company highlighted its consistent financial performance since listing, with year-on-year growth in revenue and Profit After Tax (PAT) and reiterated its long-term revenue target of approximately **₹400 crore by FY2028**.
2. Management shared updates on the expansion of its oncology business, including the dedicated cancer hospital, and stated that **cardiology, oncology and neurosurgery** are expected to be the key growth drivers in the coming years.
3. The Company informed that it is **in the process of submitting a bid** for the establishment of a **100-seat Medical College** under the **Public-Private Partnership (PPP)** model. The Company is also establishing nursing and paramedical colleges to strengthen its integrated healthcare ecosystem.
4. Management also shared updates on the proposed **Bone Marrow Transplant (BMT) Facility**, operational performance, occupancy targets, doctor retention strategy and the evolving business mix.
5. The Company further informed that it has initiated preparatory activities for migration to the **Main Board**, subject to fulfilment of applicable eligibility criteria and receipt of necessary regulatory approvals. Management also shared that it is evaluating the acquisition of a **70-bed hospital** to strengthen its regional presence.

No **Unpublished Price Sensitive Information (UPSI)**, as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015, was shared or discussed during the course of the webinar. The information shared during the interaction was based on information already available in the public domain and/or previously disclosed by the Company.

This is for your information and record.

Thanking you.

Yours faithfully,

For Asarfi Hospital Limited

Sudipa Singh

CS Sudipa Singh
Company Secretary & Compliance Officer

Asarfi Hospital Ltd. Dhanbad